126 related articles for article (PubMed ID: 37327527)
21. Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors.
Ribeiro DD; Lijfering WM; Rosendaal FR; Cannegieter SC
J Thromb Haemost; 2016 Aug; 14(8):1572-8. PubMed ID: 27214710
[TBL] [Abstract][Full Text] [Related]
22. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.
Bala MM; Paszek E; Lesniak W; Wloch-Kopec D; Jasinska K; Undas A
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012534. PubMed ID: 30004572
[TBL] [Abstract][Full Text] [Related]
23. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
[TBL] [Abstract][Full Text] [Related]
25. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
[TBL] [Abstract][Full Text] [Related]
26. Oral apixaban for the treatment of acute venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
[TBL] [Abstract][Full Text] [Related]
27. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department.
Deitelzweig S; Hlavacek P; Mardekian J; Rosenblatt L; Russ C; Tuell K; Lingohr-Smith M; Lin J; Guo JD
Hosp Pract (1995); 2020 Feb; 48(1):41-48. PubMed ID: 31976776
[No Abstract] [Full Text] [Related]
28. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Huang J; Cao Y; Liao C; Wu L; Gao F
Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
[TBL] [Abstract][Full Text] [Related]
29. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
Bleker SM; Cohen AT; Büller HR; Agnelli G; Gallus AS; Raskob GE; Weitz JI; Curto M; Sisson M; Middeldorp S
Thromb Haemost; 2016 Nov; 116(6):1159-1164. PubMed ID: 27583312
[TBL] [Abstract][Full Text] [Related]
30. The association of statin therapy with the risk of recurrent venous thrombosis.
Smith NL; Harrington LB; Blondon M; Wiggins KL; Floyd JS; Sitlani CM; McKnight B; Larson EB; Rosendaal FR; Heckbert SR; Psaty BM
J Thromb Haemost; 2016 Jul; 14(7):1384-92. PubMed ID: 27061794
[TBL] [Abstract][Full Text] [Related]
31. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.
Larsen TL; Garresori H; Brekke J; Enden T; Frøen H; Jacobsen EM; Quist-Paulsen P; Porojnicu AC; Ree AH; Torfoss D; Osvik Velle E; Skuterud Wik H; Ghanima W; Sandset PM; Dahm AEA
J Thromb Haemost; 2022 May; 20(5):1166-1181. PubMed ID: 35114046
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
Brandt W; Brown C; Wang TF; Tagalakis V; Shivakumar S; Ciuffini LA; Mallick R; Wells PS; Carrier M
Thromb Res; 2022 Aug; 216():8-10. PubMed ID: 35660801
[TBL] [Abstract][Full Text] [Related]
34. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
35. Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.
Hicks AM; DeRosa A; Raj M; Do R; Yu KH; Lowery MA; Varghese A; O'Reilly EM
Clin Colorectal Cancer; 2018 Jun; 17(2):e207-e216. PubMed ID: 29306522
[TBL] [Abstract][Full Text] [Related]
36. Early thrombosis after iliac stenting for venous outflow occlusion is related to disease severity and type of anticoagulation.
Marston WA; Browder SE; Iles K; Griffith A; McGinigle KL
J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1399-1407.e1. PubMed ID: 33667740
[TBL] [Abstract][Full Text] [Related]
37. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
[TBL] [Abstract][Full Text] [Related]
38. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial.
Woller SC; Stevens SM; Kaplan D; Wang TF; Branch DW; Groat D; Wilson EL; Armbruster B; Aston VT; Lloyd JF; Rondina MT; Elliott CG
Blood Adv; 2022 Mar; 6(6):1661-1670. PubMed ID: 34662890
[TBL] [Abstract][Full Text] [Related]
39. Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Mitrovic D; Emmens W; Naimi A; van der Mijle A; Veeger N; van Roon E; van den Bemt P
Clin Drug Investig; 2022 Jul; 42(7):593-598. PubMed ID: 35675030
[TBL] [Abstract][Full Text] [Related]
40. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.
Zhang J; Atalla M; Mallick R; Wells PS; Carrier M
J Thromb Thrombolysis; 2021 Apr; 51(3):720-724. PubMed ID: 33079379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
